Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Condensed Consolidated Statements Of Operations        
Revenues, net $ 167,598 $ 118,192 $ 585,923 $ 851,437
Operating expenses:        
Cost of implants and other costs 37,687 19,105 124,325 139,355
Selling, general and administrative 626,941 576,505 1,571,404 1,279,898
Termination of licensing agreement 132,804 3,639,694
Loss on settlement of sub-licenses 118,027
Depreciation and amortization 20,338 28,908 21,706 96,197
Total operating expenses 684,966 624,518 1,850,239 5,273,171
Loss from operations (517,368) (506,326) (1,264,316) (4,421,734)
Other income (expenses):        
Interest expense, net (214,192) (164,742) (602,551) (327,396)
(Loss) gain on change in fair value of derivative liability (1,877,231) (26,403) (2,344,272) 77,765
Total other income (expenses) (2,091,423) (191,145) (2,946,823) (249,631)
Loss before income taxes (2,608,791) (697,471) (4,211,139) (4,671,365)
Income taxes
Net loss $ (2,608,791) $ (697,471) $ (4,211,139) $ (4,671,365)
Net loss per common share, basic and diluted $ (0.02) $ 0.00 $ (0.03) $ (0.03)
Weighted average number of common shares outstanding, basic and diluted 168,832,544 158,060,044 166,397,421 153,016,644